Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (151-160 of 252) with videos related to

Pageof 26
Sort By:
Blood Advances|December 15, 2021
SARS-CoV-2-neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphomaJakob J Malin, Veronica Di Cristanziano, Carola Horn, et al.
The Journal of Molecular Diagnostics : JMD|August 4, 2020
Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral BiopsyManuel Montesinos-Rongen, Anna Brunn, Armin Tuchscherer, et al.
Leukemia & Lymphoma|December 24, 2015
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study GroupStephanie Sasse, Magdalena Alram, Horst Müller, et al.
The Lancet. Oncology|September 11, 2016
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study GroupStefanie Kreissl, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology|March 24, 2024
Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T-cell therapyDennis A Eichenauer, Jan-Michel Heger, Isabel Kruschel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
British Journal of Haematology|August 16, 2021
Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Stefanie Kreissl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study groupBoris Böll, Helen Goergen, Nils Arndt, et al.
Blood Advances|June 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin LymphomaSimon Leiders, Dominic Ufton, Helen Kaul, et al.
Blood|September 16, 2011
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphomaBoris Böll, Henning Bredenfeld, Helen Görgen, et al.
Pageof 26

Showing results (151-160 of 252) with videos related to

Sort By:
Pageof 26
Blood Advances|December 15, 2021
SARS-CoV-2-neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphomaJakob J Malin, Veronica Di Cristanziano, Carola Horn, et al.
The Journal of Molecular Diagnostics : JMD|August 4, 2020
Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral BiopsyManuel Montesinos-Rongen, Anna Brunn, Armin Tuchscherer, et al.
Leukemia & Lymphoma|December 24, 2015
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study GroupStephanie Sasse, Magdalena Alram, Horst Müller, et al.
The Lancet. Oncology|September 11, 2016
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study GroupStefanie Kreissl, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology|March 24, 2024
Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T-cell therapyDennis A Eichenauer, Jan-Michel Heger, Isabel Kruschel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
British Journal of Haematology|August 16, 2021
Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Stefanie Kreissl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study groupBoris Böll, Helen Goergen, Nils Arndt, et al.
Blood Advances|June 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin LymphomaSimon Leiders, Dominic Ufton, Helen Kaul, et al.
Blood|September 16, 2011
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphomaBoris Böll, Henning Bredenfeld, Helen Görgen, et al.
Pageof 26